RETAIL RICHES

Texas billionaire and family reign as the world’s richest clan

The Walton family fortune grew astoundingly in the past year — to the tune of $23 billion. Photo via Getty Images

It's hardly a surprise that America's Walton family, including Fort Worth billionaire Alice Walton, remains the world's richest family. What's truly stunning is how much their wealth has grown in the past year — by more than $23 billion.

In once again crowning the Waltons the world's richest family, the Bloomberg news service recently reported that their collective fortune had risen by $23 billion in the past year due to the climbing stock price of the Walmart retail chain. Sam Walton opened the first Walmart store in 1962.

Descendants of Sam and his brother, Bud, control more than 1.3 billion shares of Walmart stock either directly or through family trusts, Bloomberg says. Even though the Waltons have liquidated $6 billion in Walmart stock this year, they're now worth more in 2021 than they were in 2020.

As of mid-September, the Waltons were worth $238.2 billion, according to Bloomberg. That's almost $100 billion above the next richest family in the world, the Mars family of candy and pet care fame. Last year, Bloomberg pegged the Waltons' fortune at $215 billion.

To put the Waltons' one-year, $23 billion bump in wealth into perspective, Bloomberg estimates the net worth of Walmart heir Lukas Walton at $22 billion.

Alice Walton ranks as the second richest person in Texas (No. 1 is Elon Musk, at more than $200 billion), but she's not the richest Walmart heir. As of September 27, Bloomberg estimated Walton's net worth at $61.9 billion, making her the 19th richest person in the world. Ahead of her are brothers Jim ($63.7 billion, No. 17 worldwide) and Rob ($63.3 billion, No. 18 worldwide).

Not everyone is impressed with the Waltons' mountain of money. In February, U.S. Sen. Bernie Sanders, an independent from Vermont, branded the Waltons "the poster child for greed," based on the retailer's low starting wage. Walmart recently raised its minimum pay for hourly workers from $11 to $12.

"This is a family that is incredibly wealthy," Sanders said of the Waltons before the wage increase took effect.

"One of their owners spend[s] zillions of dollars on antique cars. They've got mansions. They have all kinds of art collections," the senator told CNN. "But somehow or another they can't pay their starting wage at more than 11 bucks an hour."

------

This article originally ran on CultureMap.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted